Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Knuf

Showing results (91-100 of 113) with videos related to

Pageof 12
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 28, 2020
Gerd E Gross, Lisa Eisert, Hans Wilhelm Doerr, et al.
Vaccine|March 23, 2011
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old childrenMarkus Knuf, Anna Pantazi-Chatzikonstantinou, Ulrich Pfletschinger, et al.
Frontiers in Immunology|July 24, 2019
Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis VaccinesSusanna Esposito, Paola Stefanelli, Norman K Fry, et al.
The Pediatric Infectious Disease Journal|April 3, 2012
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?Susanna Esposito, Robert Cohen, Javier Diez Domingo, et al.
European Journal of Pediatrics|January 3, 2024
Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in GermanyMaximilian David Mauritz, Ulrich von Both, Christian Dohna-Schwake, et al.
Cancers|November 27, 2021
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving <i>EPC2</i> and <i>GULP1</i>Claudia Paret, Nadine Lehmann, Hannah Bender, et al.
Journal of Medical Virology|August 31, 2022
Association of viral load with TRAIL, IP-10, CRP biomarker signature and disease severity in children with respiratory tract infection or fever without source: A prospective, multicentre cohort studyCihan Papan, Alberto Argentiero, Ortwin Adams, et al.
Health and Quality of Life Outcomes|May 24, 2019
A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal diseaseOle Marten, Florian Koerber, David Bloom, et al.
The Lancet. Child & Adolescent Health|May 16, 2025
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trialAlasdair P S Munro, Simon B Drysdale, Katrina Cathie, et al.
The New England Journal of Medicine|December 29, 2023
Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsSimon B Drysdale, Katrina Cathie, Florence Flamein, et al.
Pageof 12

Showing results (91-100 of 113) with videos related to

Sort By:
Pageof 12
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 28, 2020
Gerd E Gross, Lisa Eisert, Hans Wilhelm Doerr, et al.
Vaccine|March 23, 2011
An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old childrenMarkus Knuf, Anna Pantazi-Chatzikonstantinou, Ulrich Pfletschinger, et al.
Frontiers in Immunology|July 24, 2019
Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis VaccinesSusanna Esposito, Paola Stefanelli, Norman K Fry, et al.
The Pediatric Infectious Disease Journal|April 3, 2012
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?Susanna Esposito, Robert Cohen, Javier Diez Domingo, et al.
European Journal of Pediatrics|January 3, 2024
Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in GermanyMaximilian David Mauritz, Ulrich von Both, Christian Dohna-Schwake, et al.
Cancers|November 27, 2021
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving <i>EPC2</i> and <i>GULP1</i>Claudia Paret, Nadine Lehmann, Hannah Bender, et al.
Journal of Medical Virology|August 31, 2022
Association of viral load with TRAIL, IP-10, CRP biomarker signature and disease severity in children with respiratory tract infection or fever without source: A prospective, multicentre cohort studyCihan Papan, Alberto Argentiero, Ortwin Adams, et al.
Health and Quality of Life Outcomes|May 24, 2019
A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal diseaseOle Marten, Florian Koerber, David Bloom, et al.
The Lancet. Child & Adolescent Health|May 16, 2025
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trialAlasdair P S Munro, Simon B Drysdale, Katrina Cathie, et al.
The New England Journal of Medicine|December 29, 2023
Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsSimon B Drysdale, Katrina Cathie, Florence Flamein, et al.
Pageof 12